Published in Cancer Weekly, February 15th, 2000
The data, from a Phase III trial, showed docetaxel to be well tolerated among patients with metastatic or unresectable localized NSCLC who were randomized to single-agent therapy with docetaxel. Patients treated with docetaxel, a taxane, also had a significantly better survival at 20 months than patients who were assigned to receive best supportive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.